NASDAQ:IONS
Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.'s revenue grew 33.8% in fiscal 2025 to $943.7M while operating margin rose to −40.4%. Free cash flow was −$320.0M, −33.9% of revenue, and the diluted share count rose 7.0%.Summary generated from Ionis Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$943.7M
Revenue growth+33.8%
Revenue, 5-yr CAGR+5.3%
Gross margin98.3%
Operating margin−40.4%
Net margin−40.4%
ROIC−17.1%
Return on equity−70.8%
Debt / equity3.71
Free cash flow−$320.0M
FCF margin−33.9%
Share count change+7.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 810 | 587 | 788 | 705 | 944 |
| Operating income | −30 | −410 | −354 | −475 | −382 |
| Net income | −29 | −270 | −366 | −454 | −381 |
| Free cash flow | 19 | −290 | −331 | −546 | −320 |
Recent filings
- 8-KRegulation FD disclosure
Sep 23, 2026 - 8-KRegulation FD disclosure
Sep 4, 2026 - 8-KRegulation FD disclosure
Sep 4, 2026 - 4Insider transaction report
Sep 2, 2026 - 4Insider transaction report
Sep 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 29, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026 - 8-KRegulation FD disclosure
Jul 10, 2026